SBI Capital Markets Limited ("Manager to the Offer") has submitted to BSE a copy of Public Announcement for the attention of the Public Shareholders of Bliss GVS Pharma Ltd under Regulation ....

Open offer triggeredListed-company acquisitionStrategic Transactions View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.6%Reaction day

₹301.00

prior close

₹317.95

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.6%+4.1% vs market

Pharmaceuticals peers, median of 166sector+0.8%+4.8% vs sector

On the reaction day the stock moved 4.1 pts more than Nifty Microcap 250 and 4.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.5

15m

-0.3

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.6+1.6+4.1+0.8+4.8

Next day

+26.6+2.3+24.3+1.4+25.2

+31.9+2.3+29.6+1.4+30.5

+41.0+1.6+39.4+0.8+40.2

+33.7+0.5+33.2+0.4+33.3

+44.8+1.6+43.2+0.8+44.0

+50.6+2.7+47.9+0.5+50.2

15d

+51.1+5.4+45.7+1.3+49.8

+63.3+7.3+56.0+3.4+59.8

+51.7+8.6+43.1+5.5+46.1

+86.1+13.0+73.1+8.2+77.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anupam Rasayan India Limited has announced an open offer to acquire up to 2,77,26,848 equity shares (26% of expanded voting capital) of Bliss GVS Pharma Ltd at ₹299 per share. This offer, worth up to ₹829 crore assuming full acceptance, is triggered by Anupam Rasayan's agreement to purchase 43.30% stake (₹1,369 crore) from existing promoters and certain shareholders including Shruti Vishal Rao, Narsimha Shibroor Kamath, and Gulbarga Trading. After completing both transactions (with full tender acceptance), Anupam Rasayan will hold 69.51% of Bliss GVS Pharma and become the new promoter. The existing promoter group will exit and be reclassified as public shareholders. The offer is not conditional on minimum acceptance and the acquirer has confirmed no delisting plans.

Likely market impact

This open offer gives public shareholders a chance to exit at ₹299 per share (cash). The stock may trade near the offer price as the market assesses whether Anupam Rasayan's entry will create value in the pharma company. Shareholders who tender will receive cash; those who don't will remain as public shareholders with reduced stake.